Research graph
References from Superior diagnostic efficacy and cost advantage of FibroTouch over CHI3L1 for liver fibrosis in Chinese patients with chronic liver disease. Local targets link to admitted publications; unresolved targets remain external evidence.
Global burden of major chronic liver diseases in 2021
10.1111/liv.70058 · 2025 · External reference
Global and Chinese burden of non-alcoholic fatty liver disease in chronic liver disease: Findings from the Global Burden of Disease Study 2021
10.1097/cm9.0000000000003726 · 2025 · External reference
Diagnostic of FibroTouch and six serological models in assessing the degree of liver fibrosis among patients with chronic hepatic disease: A single-center retrospective study
2022 · External reference
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
10.1053/jhep.2003.50346 · 2003 · External reference
Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT
10.1111/jvh.12010 · 2013 · External reference
Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B
10.1111/j.1440-1746.2010.06383.x · 2010 · External reference
Noninvasive assessment of liver status in adult patients after the Fontan procedure
2019 · External reference
Predictive value of the red blood cell distribution width-to-platelet ratio for hepatic fibrosis
10.1080/00365521.2018.1558786 · 2019 · External reference
A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C
10.1007/s12072-017-9796-z · 2017 · External reference
Chitinase-3 like-protein-1 function and its role in diseases
10.1038/s41392-020-00303-7 · 2020 · External reference
Chitinase 3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis
10.1111/hepr.13396 · 2019 · External reference
Research advances in serum chitinase-3-like protein 1 in liver fibrosis
10.3389/fmed.2024.1372434 · 2024 · External reference
Chitinase 3-like protein 1: A diagnostic biomarker for early liver fibrosis in autoimmune liver diseases
10.3389/fimmu.2025.1504066 · 2025 · External reference
Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: An individual patient data meta-analysis
10.1016/s2468-1253(18)30124-9 · 2018 · External reference
Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)
2022 · External reference
Association of non-invasive markers with significant fibrosis in patients with nonalcoholic fatty liver disease: A cross-sectional study
10.2147/dmso.s417754 · 2023 · External reference
Diagnostic value of serum Chitinase-3-like protein 1 for liver fibrosis: A meta-analysis
10.1155/2022/3227957 · 2022 · External reference
Diagnostic performance of FibroTouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease
2021 · External reference
Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus
10.21037/apm-21-2339 · 2021 · External reference
Diagnostic value of FibroTouch and non-invasive fibrosis indexes in hepatic fibrosis with different aetiologies
10.1007/s10620-021-07049-4 · 2022 · External reference
Classification of chronic viral hepatitis: a need for reassessment
10.1016/0168-8278(91)90084-o · 1991 · External reference
Advances in non-invasive assessment of hepatic fibrosis
10.1136/gutjnl-2018-317593 · 2020 · External reference
Non-invasive assessment of liver fibrosis in hepatitis B patients
10.3390/jcm13041046 · 2024 · External reference
Personalized translational medicine: Investigating YKL-40 as early biomarker for clinical risk stratification in hepatocellular carcinoma recurrence post-liver transplantation
10.5500/wjt.v15.i2.103036 · 2025 · External reference
The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases
10.1002/jcla.23200 · 2020 · External reference
Serum CHI3L1 as a diagnostic marker and risk factor for liver fibrosis in HBeAg-negative chronic hepatitis B
2022 · External reference
Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China
10.1016/j.hbpd.2020.05.009 · 2020 · External reference
Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease
10.1038/srep35282 · 2016 · External reference
